

## RIGHT Checklist

Section/Topic	Item No	Item	Reported on Page Number/Line Number	Reported on Section/Paragraph
<b>Basic information</b>				
Title/subtitle	1a	Identify the report as a guideline, that is, with "guideline(s)" or "recommendation(s)" in the title.	P1/L1-2	Title
	1b	Describe the year of publication of the guideline.	P1/L2	Title
	1c	Describe the focus of the guideline, such as screening, diagnosis, treatment, management, prevention, or others.	NA	NA
Executive summary	2	Provide a summary of the recommendations contained in the guideline.	NA	NA
Abbreviations and acronyms	3	Define new or key terms, and provide a list of abbreviations and acronyms if applicable.	NA	NA
Corresponding developer	4	Identify at least 1 corresponding developer or author who can be contacted about the guideline.	P2/L25-44	Correspondence to:
<b>Background</b>				
Brief description of the health problem(s)	5	Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem.	NA	NA
Aim(s) of the guideline and specific objectives	6	Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings.	P7/L104-111	Introduction
Target population(s)	7a	Describe the primary population(s) that is affected by the recommendation(s) in the guideline.	P7/L104-111	Introduction
	7b	Describe any subgroups that are given special consideration in the guideline.	NA	NA
End users and settings	8a	Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and policymakers) and other potential users of the guideline.	P7/L104-111	Introduction
	8b	Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or inpatient facilities.	P7/L104-111	Introduction
Guideline development groups	9a	Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewers, systematic review team, and methodologists).	P3/L49-56 P29-30/L602-616	Contributions Acknowledgments
	9b	List all individuals involved in developing the guideline, including their title, role(s), and institutional affiliation(s).	P1/L4-7	Authors

<b>Evidence</b>				
Health care questions	10a	State the key questions that were the basis for the recommendations in PICO (population, intervention, comparator, and outcome) or other format as appropriate.	NA	NA
	10b	Indicate how the outcomes were selected and sorted.	NA	NA
Systematic reviews	11a	Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used.	P7/L114-118	Introduction
	11b	If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and describe how the risk of bias was evaluated) and whether they were updated.	P7/L114-118	Introduction
Assessment of the certainty of the body of evidence	12	Describe the approach used to assess the certainty of the body of evidence.	P7/L114-118	Introduction
<b>Recommendations</b>				
Recommendations	13a	Provide clear, precise, and actionable recommendations.	P9, P10, P12,P14, P16,P17,P18,P20, P21,P22,P23,P24,P26, P27,P29	
	13b	Present separate recommendations for important subgroups if the evidence suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups.	NA	NA
	13c	Indicate the strength of recommendations and the certainty of the supporting evidence.	P9, P10, P12,P14, P16,P17,P18,P20, P21,P22,P23,P24,P26, P27,P29	
Rationale/explanation for recommendations	14a	Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation.	NA	NA
	14b	Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost-effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation.	NA	NA
	14c	Describe other factors taken into consideration when formulating the recommendations, such as equity, feasibility, and acceptability.	NA	NA

Evidence to decision processes	15	Describe the processes and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used).	NA	NA
--------------------------------	----	--	----	----

<b>Review and quality assurance</b>				
External review	16	Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed.	NA	NA
Quality assurance	17	Indicate whether the guideline was subjected to a quality assurance process. If yes, describe the process.	NA	NA
<b>Funding and declaration and management of interests</b>				
Funding source(s) and role(s) of the funder	18a	Describe the specific sources of funding for all stages of guideline development.	P30/L622	Footnote
	18b	Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.	NA	NA
Declaration and management of interests	19a	Describe what types of conflicts (financial and nonfinancial) were relevant to guideline development.	P30/L619	Footnote
	19b	Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.	P30/L619	Footnote
<b>Other information</b>				
Access	20	Describe where the guideline, its appendices, and other related documents can be accessed.	NA	NA
Suggestions for further research	21	Describe the gaps in the evidence and/or provide suggestions for future research.	P5	Key recommendations
Limitations of the guideline	22	Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations.	NA	NA

RIGHT = Reporting Items for practice Guidelines in HealThcare.

Article information: <https://dx.doi.org/10.21037/hbsn-24-329>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.